NO330756B1 - N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft - Google Patents

N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft Download PDF

Info

Publication number: NO330756B1
Authority: NO; Norway
Prior art keywords: cancer; compound; use according; pharmaceutically acceptable; pain
Prior art date: 2002-08-23

Application number

NO20050689A

Other languages

English (en)

Norwegian (no)

Other versions

NO20050689L (no

Inventor

Francis Thomas Boyle

Marianne Ashford

David William Tonge

Sian Tomiko Taylor

Andrew Mark Hughes

Donna Johnstone

Nigel Charles Barrass

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-23

Filing date

2005-02-09

Publication date

2011-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO330756(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-02-09 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-03-21 Publication of NO20050689L publication Critical patent/NO20050689L/no

2011-07-04 Publication of NO330756B1 publication Critical patent/NO330756B1/no

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 81
201000011510 cancer Diseases 0.000 title claims abstract description 66
150000003839 salts Chemical class 0.000 title claims abstract description 21
238000011282 treatment Methods 0.000 title claims abstract description 19
FJHHZXWJVIEFGJ-UHFFFAOYSA-N N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 title claims abstract description 4
150000001875 compounds Chemical class 0.000 claims abstract description 92
241001465754 Metazoa Species 0.000 claims abstract description 14
206010061289 metastatic neoplasm Diseases 0.000 claims description 11
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
230000001394 metastastic effect Effects 0.000 claims description 9
206010060862 Prostate cancer Diseases 0.000 claims description 8
206010041067 Small cell lung cancer Diseases 0.000 claims description 7
210000001072 colon Anatomy 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
206010033128 Ovarian cancer Diseases 0.000 claims description 5
206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
201000001441 melanoma Diseases 0.000 claims description 5
206010009944 Colon cancer Diseases 0.000 claims description 4
208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
208000029742 colonic neoplasm Diseases 0.000 claims description 4
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
210000002307 prostate Anatomy 0.000 claims description 4
206010038038 rectal cancer Diseases 0.000 claims description 4
201000001275 rectum cancer Diseases 0.000 claims description 4
206010006187 Breast cancer Diseases 0.000 claims description 3
208000026310 Breast neoplasm Diseases 0.000 claims description 3
206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
206010017758 gastric cancer Diseases 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
210000004072 lung Anatomy 0.000 claims description 3
210000005075 mammary gland Anatomy 0.000 claims description 3
210000000664 rectum Anatomy 0.000 claims description 3
201000011549 stomach cancer Diseases 0.000 claims description 3
206010005003 Bladder cancer Diseases 0.000 claims description 2
208000003174 Brain Neoplasms Diseases 0.000 claims description 2
206010008342 Cervix carcinoma Diseases 0.000 claims description 2
206010014733 Endometrial cancer Diseases 0.000 claims description 2
206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
206010029260 Neuroblastoma Diseases 0.000 claims description 2
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
206010038389 Renal cancer Diseases 0.000 claims description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
201000010881 cervical cancer Diseases 0.000 claims description 2
210000003679 cervix uteri Anatomy 0.000 claims description 2
201000010536 head and neck cancer Diseases 0.000 claims description 2
208000014829 head and neck neoplasm Diseases 0.000 claims description 2
201000010982 kidney cancer Diseases 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
210000005229 liver cell Anatomy 0.000 claims description 2
201000000050 myeloid neoplasm Diseases 0.000 claims description 2
201000000498 stomach carcinoma Diseases 0.000 claims description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
210000003932 urinary bladder Anatomy 0.000 claims description 2
201000005112 urinary bladder cancer Diseases 0.000 claims description 2
208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
208000024770 Thyroid neoplasm Diseases 0.000 claims 1
201000004101 esophageal cancer Diseases 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
208000014018 liver neoplasm Diseases 0.000 claims 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
230000000683 nonmetastatic effect Effects 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
201000002510 thyroid cancer Diseases 0.000 claims 1
208000002193 Pain Diseases 0.000 abstract description 28
102100033902 Endothelin-1 Human genes 0.000 description 23
101800004490 Endothelin-1 Proteins 0.000 description 23
102000005962 receptors Human genes 0.000 description 22
108020003175 receptors Proteins 0.000 description 22
230000000694 effects Effects 0.000 description 21
210000004027 cell Anatomy 0.000 description 20
210000000963 osteoblast Anatomy 0.000 description 16
108091054455 MAP kinase family Proteins 0.000 description 14
102000043136 MAP kinase family Human genes 0.000 description 14
206010027476 Metastases Diseases 0.000 description 10
210000004204 blood vessel Anatomy 0.000 description 10
210000000988 bone and bone Anatomy 0.000 description 10
230000034994 death Effects 0.000 description 10
231100000517 death Toxicity 0.000 description 10
102000002045 Endothelin Human genes 0.000 description 9
108050009340 Endothelin Proteins 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 8
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
206010027452 Metastases to bone Diseases 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
230000026731 phosphorylation Effects 0.000 description 6
238000006366 phosphorylation reaction Methods 0.000 description 6
102000010180 Endothelin receptor Human genes 0.000 description 5
108050001739 Endothelin receptor Proteins 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
210000000245 forearm Anatomy 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
102100038358 Prostate-specific antigen Human genes 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000004913 activation Effects 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
208000010658 metastatic prostate carcinoma Diseases 0.000 description 4
238000000034 method Methods 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
229940118365 Endothelin receptor antagonist Drugs 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002308 endothelin receptor antagonist Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
208000019622 heart disease Diseases 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
239000005526 vasoconstrictor agent Substances 0.000 description 3
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
208000032382 Ischaemic stroke Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037182 bone density Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
230000007170 pathology Effects 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
210000005267 prostate cell Anatomy 0.000 description 2
208000002815 pulmonary hypertension Diseases 0.000 description 2
230000004044 response Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
231100000759 toxicological effect Toxicity 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 1
206010049589 Afterbirth pain Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000025978 Athletic injury Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
229940121889 Endothelin A receptor antagonist Drugs 0.000 description 1
102000003965 Endothelin-2 Human genes 0.000 description 1
108090000387 Endothelin-2 Proteins 0.000 description 1
102100029109 Endothelin-3 Human genes 0.000 description 1
108010072844 Endothelin-3 Proteins 0.000 description 1
102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 1
108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022562 Intermittent claudication Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
206010033425 Pain in extremity Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000000450 Pelvic Pain Diseases 0.000 description 1
206010034576 Peripheral ischaemia Diseases 0.000 description 1
102000007982 Phosphoproteins Human genes 0.000 description 1
108010089430 Phosphoproteins Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000010040 Sprains and Strains Diseases 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000006909 anti-apoptosis Effects 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
230000008321 arterial blood flow Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
238000007469 bone scintigraphy Methods 0.000 description 1
210000002302 brachial artery Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
ZGOVYTPSWMLYOF-QEADGSHQSA-N chembl1790180 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@H](CCC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)[C@H](C)O)=O)NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZGOVYTPSWMLYOF-QEADGSHQSA-N 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
208000002925 dental caries Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
MLFJHYIHIKEBTQ-IYRKOGFYSA-N endothelin 2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 MLFJHYIHIKEBTQ-IYRKOGFYSA-N 0.000 description 1
239000003062 endothelin A receptor antagonist Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000002710 external beam radiation therapy Methods 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002682 general surgery Methods 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
230000036433 growing body Effects 0.000 description 1
230000026781 habituation Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
-1 hydrogen halides Chemical class 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000000684 melanotic effect Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000011164 ossification Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
230000007824 polyneuropathy Effects 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000011176 pooling Methods 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000861 pro-apoptotic effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000031539 regulation of cell division Effects 0.000 description 1
230000025053 regulation of cell proliferation Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
230000011664 signaling Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000011521 systemic chemotherapy Methods 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000012384 transportation and delivery Methods 0.000 description 1
206010044652 trigeminal neuralgia Diseases 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000002455 vasospastic effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20050689A 2002-08-23 2005-02-09 N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft NO330756B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0219660.8A GB0219660D0 (en)	2002-08-23	2002-08-23	Therapeutic use
PCT/GB2003/003653 WO2004018044A2 (fr)	2002-08-23	2003-08-20	Usage therapeutique

Publications (2)

Publication Number	Publication Date
NO20050689L NO20050689L (no)	2005-03-21
NO330756B1 true NO330756B1 (no)	2011-07-04

Family

ID=9942847

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20050689A NO330756B1 (no)	2002-08-23	2005-02-09	N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft

Country Status (31)

Country	Link
US (2)	US7820679B2 (fr)
EP (2)	EP2072082A3 (fr)
JP (2)	JP3663202B2 (fr)
KR (1)	KR20050035280A (fr)
CN (1)	CN100467023C (fr)
AR (1)	AR041037A1 (fr)
AT (1)	ATE427773T1 (fr)
AU (1)	AU2003255835B8 (fr)
BR (1)	BR0313655A (fr)
CA (1)	CA2496476C (fr)
CL (1)	CL2003001692A1 (fr)
CY (1)	CY1110712T1 (fr)
DE (1)	DE60327084D1 (fr)
DK (1)	DK1545710T3 (fr)
ES (1)	ES2323309T3 (fr)
GB (1)	GB0219660D0 (fr)
IL (1)	IL166730A0 (fr)
IS (1)	IS2704B (fr)
MX (1)	MXPA05001862A (fr)
MY (2)	MY136449A (fr)
NO (1)	NO330756B1 (fr)
NZ (1)	NZ538114A (fr)
PL (1)	PL375561A1 (fr)
PT (1)	PT1545710E (fr)
RU (1)	RU2340343C2 (fr)
SA (1)	SA03240363B1 (fr)
SI (1)	SI1545710T1 (fr)
TW (1)	TWI302912B (fr)
UA (1)	UA82071C2 (fr)
WO (1)	WO2004018044A2 (fr)
ZA (1)	ZA200501267B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0403744D0 (en)	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
GB0425854D0 (en) *	2004-11-25	2004-12-29	Astrazeneca Ab	Therapeutic treatment
GB0514743D0 (en) *	2005-07-19	2005-08-24	Astrazeneca Ab	Salt
WO2007111350A1 (fr) *	2006-03-28	2007-10-04	Osaka Bioscience Institute	agent inhibiteur d'angiogenese ou d'invasion cancereuse de cellules de type mesenchymal ou amiboide
US20090062246A1 (en) *	2007-08-17	2009-03-05	Astrazeneca Ab	Therapeutic treatment-014
EP2209501B1 (fr) *	2007-10-12	2011-12-14	AstraZeneca AB	Composition de Zibotentane comprenant du mannitol et de la cellulose microcristalline
WO2009068906A2 (fr) *	2007-11-26	2009-06-04	Astrazeneca Ab	Combinaisons comprenant zd4054 et un inhibiteur 172 des kinases de la famille src
WO2010004337A1 (fr) *	2008-07-10	2010-01-14	Astrazeneca Ab	Combinaison comprenant du n-(3-méthoxy-5-méthylpyrazine-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phényle)pyridine-3-sulfonamide et du pemetrexed
EP2709622A4 (fr) *	2011-05-17	2015-03-04	Plexxikon Inc	Modulation de kinase et indications pour celle-ci
CN102491973A (zh) *	2011-12-15	2012-06-13	南京友杰医药科技有限公司	Zd-4054的合成方法
KR101855382B1 (ko) *	2015-12-31	2018-05-04	경북대학교 산학협력단	설폰아마이드계 화합물을 유효성분으로 포함하는 암의 예방, 치료 및 전이 억제용 약학적 조성물
US12233061B2 (en)	2019-02-12	2025-02-25	The University Court Of The University Of Glasgow	Microvascular angina

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5464853A (en)	1993-05-20	1995-11-07	Immunopharmaceutics, Inc.	N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en)	1993-05-20	1996-05-07	Immunopharmaceutics, Inc.	N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en)	1993-05-20	1997-01-07	Texas Biotechnology Corporation	Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (fr)	1991-04-25	1996-02-11	Hoffmann La Roche
RU2086544C1 (ru)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (fr)	1992-02-24	1994-06-01	Squibb & Sons Inc
NZ247440A (en)	1992-05-06	1995-04-27	Squibb & Sons Inc	Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en)	1993-08-30	1999-10-12	Bristol-Myers Squibb Co.	Sulfonamide endothelin antagonists
US6063911A (en)	1993-12-01	2000-05-16	Marine Polymer Technologies, Inc.	Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en)	1994-03-31	1995-04-26	Zeneca Ltd	Nitrogen derivatives
DK0755393T3 (da) *	1994-04-15	2001-12-17	Upjohn Co	Nye krystalformer af 1-[5-methansulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazin
GB9409618D0 (en)	1994-05-13	1994-07-06	Zeneca Ltd	Pyridine derivatives
AU3642795A (en)	1994-09-27	1996-04-19	Merck & Co., Inc.	Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en)	1994-12-01	1996-06-05	Zeneca Ltd	N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) *	1995-06-07	2003-08-15	Зенека Лімітед	Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en)	1995-06-22	1995-08-23	Zeneca Ltd	Heterocyclic compounds
US5780435A (en)	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en)	1997-03-07	1997-04-23	Zeneca Ltd	Chemical process
AU3011299A (en)	1998-03-23	1999-10-18	Merck & Co., Inc.	Combination therapy for the treatment of benign prostatic hyperplasia
US6673832B1 (en)	1998-05-04	2004-01-06	Gudarz Davar	Methods for identifying compounds for treating pain
ATE457169T1 (de)	1998-10-15	2010-02-15	Imp Innovations Ltd	Verbindungen für die behandlung von gewichtsverlust
US7566452B1 (en)	1999-05-04	2009-07-28	New York University	Cancer treatment with endothelin receptor antagonists
US6545048B1 (en)	1999-06-29	2003-04-08	California Institute Of Technology	Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
EP1741713A3 (fr)	1999-12-15	2009-09-09	Bristol-Myers Squibb Company	Biphényl-sulfonamides comme antagonistes jumalées des récepteurs endothélines.
ATE348617T1 (de)	2000-02-16	2007-01-15	Astellas Pharma Inc	Heilmittel gegen durch endothelin verursachte erkrankungen
CA2409927A1 (fr)	2000-05-31	2001-12-06	Warner-Lambert Company	Combinaisons d'un antagoniste de recepteur d'endotheline et compose anti-epileptique presentant des proprietes analgesiques ou de soulagement de la douleur
US20020055457A1 (en)	2000-08-07	2002-05-09	Janus Todd J.	Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en)	2000-08-07	2009-03-01	Abbott Lab	Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de)	2001-03-20	2002-09-26	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
WO2002049630A2 (fr) *	2000-12-21	2002-06-27	Bristol-Myers Squibb Company	Methode pour prevenir et traiter une douleur par l'administration d'un antagoniste de l'endotheline
IL157734A0 (en)	2001-03-06	2004-03-28	Cellegy Pharma Inc	Pharmaceutical compositions for the treatment of urogenital disorders
GB0108689D0 (en)	2001-04-05	2001-05-30	Medical Res Council	Neuropathologies associated with expression of TNF-a
PE20021032A1 (es)	2001-04-11	2002-11-12	Abbott Lab	Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
US20030092757A1 (en)	2001-04-11	2003-05-15	Amitabh Singh	Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr)	2001-07-12	2003-01-23	Takeda Chemical Industries, Ltd.	Agents prophylactiques/therapeutiques contre les tumeurs malignes
US20030104976A1 (en)	2001-07-23	2003-06-05	Gudarz Davar	Analgesic methods using endothelin receptor ligands
WO2003015820A1 (fr)	2001-08-10	2003-02-27	Takeda Chemical Industries, Ltd.	Medicaments combines d'agoniste de la gnrh
DE10155076A1 (de)	2001-11-09	2003-05-22	Merck Patent Gmbh	Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en)	2001-11-27	2011-07-05	The Board Of Trustees Of The University Of Illinois	Method and composition for potentiating an opiate analgesic
GB0223367D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Therapeutic treatment
GB0223854D0 (en)	2002-10-12	2002-11-20	Astrazeneca Ab	Therapeutic treatment
GB0320806D0 (en)	2003-09-05	2003-10-08	Astrazeneca Ab	Therapeutic treatment
SI1761515T1 (sl)	2003-12-20	2009-02-28	Merck Patent Gmbh	2-(hetero-)aril substituirani derivati tetrahidrokinolina
GB0403744D0 (en)	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
GB0425854D0 (en)	2004-11-25	2004-12-29	Astrazeneca Ab	Therapeutic treatment
GB0514743D0 (en)	2005-07-19	2005-08-24	Astrazeneca Ab	Salt

2002
- 2002-08-23 GB GBGB0219660.8A patent/GB0219660D0/en not_active Ceased
2003
- 2003-08-19 TW TW092122753A patent/TWI302912B/zh not_active IP Right Cessation
- 2003-08-20 UA UAA200502486A patent/UA82071C2/uk unknown
- 2003-08-20 BR BR0313655-8A patent/BR0313655A/pt not_active IP Right Cessation
- 2003-08-20 SI SI200331583T patent/SI1545710T1/sl unknown
- 2003-08-20 CN CNB038244098A patent/CN100467023C/zh not_active Expired - Fee Related
- 2003-08-20 DK DK03792501T patent/DK1545710T3/da active
- 2003-08-20 RU RU2005108349/15A patent/RU2340343C2/ru not_active IP Right Cessation
- 2003-08-20 DE DE60327084T patent/DE60327084D1/de not_active Expired - Lifetime
- 2003-08-20 EP EP09157558A patent/EP2072082A3/fr not_active Withdrawn
- 2003-08-20 ES ES03792501T patent/ES2323309T3/es not_active Expired - Lifetime
- 2003-08-20 MX MXPA05001862A patent/MXPA05001862A/es active IP Right Grant
- 2003-08-20 KR KR1020057003079A patent/KR20050035280A/ko not_active Ceased
- 2003-08-20 US US10/524,963 patent/US7820679B2/en not_active Expired - Fee Related
- 2003-08-20 AT AT03792501T patent/ATE427773T1/de active
- 2003-08-20 WO PCT/GB2003/003653 patent/WO2004018044A2/fr not_active Ceased
- 2003-08-20 AU AU2003255835A patent/AU2003255835B8/en not_active Ceased
- 2003-08-20 PL PL03375561A patent/PL375561A1/xx unknown
- 2003-08-20 NZ NZ538114A patent/NZ538114A/en not_active IP Right Cessation
- 2003-08-20 CA CA002496476A patent/CA2496476C/fr not_active Expired - Fee Related
- 2003-08-20 EP EP03792501A patent/EP1545710B1/fr not_active Expired - Lifetime
- 2003-08-20 PT PT03792501T patent/PT1545710E/pt unknown
- 2003-08-21 CL CL200301692A patent/CL2003001692A1/es unknown
- 2003-08-21 MY MYPI20033175A patent/MY136449A/en unknown
- 2003-08-21 MY MYPI20070918A patent/MY137595A/en unknown
- 2003-08-22 AR ARP030103041A patent/AR041037A1/es unknown
- 2003-08-25 JP JP2003299605A patent/JP3663202B2/ja not_active Expired - Fee Related
- 2003-10-28 SA SA03240363A patent/SA03240363B1/ar unknown
2004
- 2004-10-27 JP JP2004311829A patent/JP2005097312A/ja not_active Ceased
2005
- 2005-02-07 IL IL16673005A patent/IL166730A0/xx unknown
- 2005-02-09 NO NO20050689A patent/NO330756B1/no not_active IP Right Cessation
- 2005-02-11 ZA ZA200501267A patent/ZA200501267B/en unknown
- 2005-03-22 IS IS7766A patent/IS2704B/is unknown
2009
- 2009-06-11 CY CY20091100620T patent/CY1110712T1/el unknown
2010
- 2010-09-13 US US12/880,347 patent/US20110003831A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2496476C (fr)	2009-08-04
IS2704B (is)	2010-12-15
EP1545710B1 (fr)	2009-04-08
EP1545710A2 (fr)	2005-06-29
EP2072082A3 (fr)	2009-12-23
WO2004018044A3 (fr)	2004-05-06
CN100467023C (zh)	2009-03-11
SI1545710T1 (sl)	2009-08-31
BR0313655A (pt)	2005-06-21
RU2340343C2 (ru)	2008-12-10
UA82071C2 (en)	2008-03-11
CL2003001692A1 (es)	2005-01-21
MY137595A (en)	2009-02-27
AR041037A1 (es)	2005-04-27
JP2004083590A (ja)	2004-03-18
NZ538114A (en)	2008-02-29
WO2004018044A2 (fr)	2004-03-04
KR20050035280A (ko)	2005-04-15
ZA200501267B (en)	2006-10-25
AU2003255835B2 (en)	2007-04-05
RU2005108349A (ru)	2005-08-27
AU2003255835B8 (en)	2007-05-17
MY136449A (en)	2008-10-31
US20110003831A1 (en)	2011-01-06
PT1545710E (pt)	2009-05-26
WO2004018044A8 (fr)	2004-06-24
GB0219660D0 (en)	2002-10-02
ES2323309T3 (es)	2009-07-13
JP2005097312A (ja)	2005-04-14
TW200409768A (en)	2004-06-16
HK1077534A1 (en)	2006-02-17
EP2072082A2 (fr)	2009-06-24
US20060094729A1 (en)	2006-05-04
JP3663202B2 (ja)	2005-06-22
CA2496476A1 (fr)	2004-03-04
CY1110712T1 (el)	2015-06-10
DK1545710T3 (da)	2009-06-29
SA03240363B1 (ar)	2009-04-11
TWI302912B (en)	2008-11-11
IS7766A (is)	2005-03-22
DE60327084D1 (de)	2009-05-20
NO20050689L (no)	2005-03-21
ATE427773T1 (de)	2009-04-15
US7820679B2 (en)	2010-10-26
MXPA05001862A (es)	2005-06-03
CN1688365A (zh)	2005-10-26
PL375561A1 (en)	2005-11-28
AU2003255835A1 (en)	2004-03-11
IL166730A0 (en)	2006-01-15

Legal Events

Date	Code	Title	Description
2013-03-25	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US20110003831A1 (en)	2011-01-06	N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
RU2640180C2 (ru)	2017-12-26	Способ адъювантного лечения рака
JP2020519576A (ja)	2020-07-02	肝細胞癌の治療
WO2001060370A1 (fr)	2001-08-23	Remedes contre les maladies induites par l'endotheline
CN114588164A (zh)	2022-06-07	瑞马唑仑在预防围术期低体温和寒战中的应用
US12226454B2 (en)	2025-02-18	Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
US12156867B2 (en)	2024-12-03	Melanocortin agents for use in the therapeutic treatment of melanoma, tumors of the gastrointestinal tract, and thyroid carcinoma
AU2007203079B2 (en)	2009-12-17	N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4- [1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide as an anticancer agent
JPWO2006088088A1 (ja)	2008-07-03	Ｒｏｃｋ阻害剤を含有する疼痛治療剤
HK1077534B (en)	2009-09-11	Use of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide in the treatment of cancer
HK1133406A (en)	2010-03-26	N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3sulfonamide as analgetic agent
WO2010037892A1 (fr)	2010-04-08	Composition comprenant de la silibinine à des concentrations déterminées et préparation combinée comprenant de la silibinine et un inhibiteur de la voie pi3k/akt pour le traitement du cancer
JP2015196664A (ja)	2015-11-09	関節疾患の治療予防剤
HK1206642B (en)	2022-02-18	Method of adjuvant cancer treatment